A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: Preliminary results of RTOG 0417

International Journal of Radiation Oncology Biology Physics

Volumn 83, Issue 4, 2012, Pages 1179-1184

  Schefter, Tracey E ^a   Winter, Kathryn ^b   Kwon, Janice S ^c   Stuhr, Kelly ^d   Balaraj, Khalid ^e   Yaremko, Brian P ^f   Small Jr , William ^g   Gaffney, David K ^h  

^a UNIVERSITY OF COLORADO   (United States)

^b RTOG Statistical Center   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Anschutz Cancer Pavilion   (United States)

^e KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g NORTHWESTERN UNIVERSITY   (United States)

^h UNIVERSITY OF UTAH   (United States)

Author keywords

Bevacizumab; Cervical cancer; Chemoradiation; RTOG Phase II trial results

Indexed keywords

ADVERSE EVENTS; BEVACIZUMAB; BRACHYTHERAPY; CERVICAL CANCERS; CERVICAL CARCINOMA; CHEMORADIATION; CIS-PLATIN; COMMON TERMINOLOGY CRITERIA; DEFINITIVE RADIOTHERAPY; EXTERNAL BEAM; HEMATOLOGIC TOXICITY; MEDICAL INTERVENTION; NATIONAL CANCER INSTITUTE; NEUTROPENIA; PELVIC RADIOTHERAPY; PERFORMANCE STATUS; PHASE II;

CARDIAC RESYNCHRONIZATION THERAPY; CHEMOTHERAPY; ONCOLOGY; PLATINUM COMPOUNDS; RADIOTHERAPY; TOXICITY;

CHEMORADIOTHERAPY;

BEVACIZUMAB; CISPLATIN;

ADULT; ADVERSE OUTCOME; AGED; ARTERY THROMBOSIS; ARTICLE; BLADDER PERFORATION; BLOOD TOXICITY; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CARDIOTOXICITY; CHEMORADIOTHERAPY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HUMAN; INTESTINE PERFORATION; LEUKOPENIA; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PATIENT COMPLIANCE; PELVIC RADIOTHERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA; VAGINA BLEEDING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKOPENIA; MIDDLE AGED; NEUTROPENIA; PROSPECTIVE STUDIES; RADIOTHERAPY DOSAGE; TUMOR BURDEN; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84862679427     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.10.060     Document Type: Article

References (17)

1. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340:1137-1143.
2. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:144-153.
3. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340:1154-1161.
4. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999;17:1339-1348.
5. Peters WA III, Liu PY, Barrett RJ, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000;18:1606-1613.
6. Thomas GM. Concurrent chemotherapy and radiation for locally advanced cervical cancer: The new standard of care. Semin Radiat Oncol 2000;10:44-50.
7. Folkman J, D'Amore PA. Blood vessel formation: What is its molecular basis? Cell 1996;87:1153-1155.
8. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992;3:65-71.
9. Hlatky L, Hahnfeldt P, Tsionou C, Coleman CN. Environmental controls and effects in angiogenesis. Br J Cancer 1996;74:S151-S156.
10. Gaffney DK, Haslam D, Tsodikov A, et al. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003;56:922-928.
11. Volm M, Koomagi R, Mattern J. Interrelationships between microvessel density, expression of VEGF and resistance to doxorubicin of non-small lung cell carcinoma. Anticancer Res 1996;16:213-217.
12. Fyles AW, Milosevic M, Wong R, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998;48:149-156.
13. Willet CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature 2004;10:145-147.
14. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 2001;7:987-989.
15. Citrin D, Menard C, Camphausen K. Combining radiotherapy and angiogenesis inhibitors: Clinical trial design. Int J Radiat Oncol Biol Phys 2006;64:15-25.
16. Lanciano R, Calkins A, Bundy B, et al. Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: A Gynecologic Oncology Group study. J Cancer Oncol 2005;23(33):8289-8295.
17. Fleming T. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982;38:143-151.